An Exploratory Study of Sintilimab in Combination With Nab-paclitaxel in Patients With Advanced Recurrent or Metastatic HNSCC (Head and Neck Squamous Cell Carcinoma) After 2 or More Prior Lines of Therapy
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 03 Jun 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified July 2019).
- 16 Jul 2019 Planned initiation date changed from 1 Jun 2019 to 20 Jul 2019.
- 07 Jun 2019 New trial record